305357-79-3

Basic information

• Product Name: 3-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE
• Synonyms: 3-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE
• CAS NO: 305357-79-3
• Molecular Formula: C14H13N3
• Molecular Weight: 223.27
• Mol File: 305357-79-3.mol

Chemical Properties

• Boiling Point: 489.8°Cat760mmHg
• Flash Point: 282°C
• Appearance: /
• Density: 1.247g/cm³
• Vapor Pressure: 9.67E-10mmHg at 25°C
• Refractive Index: 1.714
• CAS DataBase Reference: 3-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(305357-79-3)
• EPA Substance Registry System: 3-(5-METHYL-1 H-BENZOIMIDAZOL-2-YL)-PHENYLAMINE(305357-79-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 305357-79-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H13N3/c1-9-5-6-12-13(7-9)17-14(16-12)10-3-2-4-11(15)8-10/h2-8H,15H2,1H3,(H,16,17)

Upstream product

• 325803-76-7 3-nitro-benzoic acid-(4-methyl-2-nitro-anilide) 
• 7647-01-0 hydrogenchloride 
• 26242-93-3 N-(4-methyl-2-nitrophenyl) benzamide 
• 548780-83-2 3-nitro-N-[2-[(3-nitrobenzoyl)amino]-4-methylphenyl]benzamide 
• 69570-94-1 5-methyl-2-(3-nitrophenyl)-1H-benzimidazole 
• 496-72-0 4-methyl-1,2-diaminobenzene 
• 99-05-8 meta-aminobenzoic acid 

Downstream Products

• 901103-67-1 C₂₂H₁₉N₃O 
• 1628798-88-8 C₂₁H₁₆BrN₃O 
• 1628798-89-9 C₂₁H₁₆N₄O₃ 
• 1628798-90-2 C₂₁H₁₆N₄O₃ 
• 1628798-91-3 C₂₃H₂₁N₃O₃ 
• 1628798-92-4 C₁₆H₁₅N₃O 
• 1112421-10-9 C₂₁H₁₇N₃O 
• 1112281-19-2 C₂₂H₁₉N₃O₂ 
• 1628798-86-6 C₂₃H₂₁N₃O₃ 
• 1628798-87-7 C₂₄H₂₃N₃O₄ 

Relevant articles and documents

Synthesis and bioactivity evaluation of 2-arylbenzimidazole analogues

Benzimidazole is an important drug intermediate. Benzimidazole analogues have shown antibacterial, antiviral, resisting parasites medicinal activity. In this paper, we used phenylenediamine as a starting material through cyclization, acylation reaction to

Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae

Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 μM, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 μM against CWL-029 and 6.3 μM against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.